These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23825999)

  • 41. Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis.
    Coppola N; Pisaturo M; Tonziello G; Sagnelli C; Sagnelli E; Angelillo IF
    BMC Infect Dis; 2012 Dec; 12():357. PubMed ID: 23245594
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection.
    Alavian SM; Tabatabaei SV
    Iran J Kidney Dis; 2010 Jul; 4(3):181-94. PubMed ID: 20622305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience.
    Abbas Z; Memon MS; Mithani H; Jafri W; Hamid S
    Antivir Ther; 2014; 19(5):463-8. PubMed ID: 24423484
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.
    Koretz RL; Pleguezuelo M; Arvaniti V; Barrera Baena P; Ciria R; Gurusamy KS; Davidson BR; Burroughs AK
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD003617. PubMed ID: 23440791
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The efficacy of the Peginterferon treatment in chronic hepatitis HDV and compensate liver cirrhosis.
    Tugui L; Dumitru M; Iacob S; Gheorghe L; Preda C; Dinu I; Becheanu G; Dumbrava M; Nicolae I; Andrei A; Lupu A; Diculescu M
    Rev Med Chir Soc Med Nat Iasi; 2014; 118(2):368-75. PubMed ID: 25076702
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 'Double-hit' pegylated interferon-alpha successfully treats Hepatitis B and Hepatitis D co-infection.
    Bhuva M; Moore M; Sen S
    Oxf Med Case Reports; 2020 Oct; 2020(10):omaa084. PubMed ID: 33343908
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Meta-analysis: antiviral treatment for hepatitis D.
    Triantos C; Kalafateli M; Nikolopoulou V; Burroughs A
    Aliment Pharmacol Ther; 2012 Mar; 35(6):663-73. PubMed ID: 22273482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.
    Miyase S; Haraoka K; Ouchida Y; Morishita Y; Fujiyama S
    J Gastroenterol; 2012 Sep; 47(9):1014-21. PubMed ID: 22382633
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.
    Druyts E; Thorlund K; Wu P; Kanters S; Yaya S; Cooper CL; Mills EJ
    Clin Infect Dis; 2013 Apr; 56(7):961-7. PubMed ID: 23243171
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study.
    Soyer OM; Baran B; Ormeci AC; Gokturk S; Aydın E; Onel D; Gulluoglu M; Karaca C; Akyuz F; Demir K; Besisik F; Kaymakoglu S
    Postgrad Med; 2016 May; 128(4):432-8. PubMed ID: 27054544
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis.
    Kitson MT; Sarrazin C; Toniutto P; Eslick GD; Roberts SK
    J Hepatol; 2014 Dec; 61(6):1247-52. PubMed ID: 25135863
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection: longitudinal analysis of a German cohort.
    Bockmann JH; Grube M; Hamed V; von Felden J; Landahl J; Wehmeyer M; Giersch K; Hall MT; Murray JM; Dandri M; Lüth S; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
    BMC Gastroenterol; 2020 Jan; 20(1):24. PubMed ID: 32000689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.
    Jacobson IM; Dore GJ; Foster GR; Fried MW; Radu M; Rafalsky VV; Moroz L; Craxi A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; De La Rosa G; Kalmeijer R; Scott J; Sinha R; Beumont-Mauviel M
    Lancet; 2014 Aug; 384(9941):403-13. PubMed ID: 24907225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatitis delta virus testing, epidemiology and management: a multicentre cross-sectional study of patients in London.
    El Bouzidi K; Elamin W; Kranzer K; Irish DN; Ferns B; Kennedy P; Rosenberg W; Dusheiko G; Sabin CA; Smith BC; Nastouli E
    J Clin Virol; 2015 May; 66():33-7. PubMed ID: 25866333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.
    Hui CK; Lai LS; Lam P; Zhang HY; Fung TT; Lai ST; Wong WM; Lo CM; Fan ST; Leung N; Lau GK;
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1171-8. PubMed ID: 16611278
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: A systematic review and meta-analysis.
    Aljumah AA; Murad MH
    Hepatol Res; 2013 Dec; 43(12):1255-63. PubMed ID: 23458104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study.
    Liu CH; Liang CC; Lin JW; Chen SI; Tsai HB; Chang CS; Hung PH; Kao JH; Liu CJ; Lai MY; Chen JH; Chen PJ; Kao JH; Chen DS
    Gut; 2008 Apr; 57(4):525-30. PubMed ID: 17881538
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Performance of Hepatitis Delta Virus (HDV) RNA Testing for the Diagnosis of Active HDV Infection: Systematic Review and Meta-analysis.
    Chen S; Zhang X; Xu L; Tian Y; Fan Z; Cao Y; Pan Z; Gao Y; Zheng S; Duan Z; Liu M; Ren F
    J Clin Transl Hepatol; 2023 Nov; 11(6):1368-1376. PubMed ID: 37719969
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.